The potential benefits and risks of the use of DMTs should be carefully considered for each patient who is pregnant or is planning to become pregnant.
Teriflunomide belongs to FDA pregnancy category X (after 2015, the FDA adopted a more descriptive system to communicate pregnancy risk information), owing to its embryotoxicity and teratogenicity, and it should therefore be avoided in these patients. Because teriflunomide is present in the blood for several months after discontinuation, women who use this drug but are planning pregnancy need to undergo an accelerated elimination procedure with cholestyramine or charcoal. The teratogenicity potential of cladribine also limits its use.
Learn more about MS in pregnancy.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Christopher Luzzio, Kerstin Hellwig. Fast Five Quiz: Relapsing-Remitting Multiple Sclerosis Management - Medscape - Jun 30, 2022.